Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells

BACKGROUND: Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms of acquired drug resistance to osimertinib have not as yet been clar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hisakane, Kakeru, Seike, Masahiro, Sugano, Teppei, Yoshikawa, Akiko, Matsuda, Kuniko, Takano, Natsuki, Takahashi, Satoshi, Noro, Rintaro, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169289/
https://www.ncbi.nlm.nih.gov/pubmed/33939301
http://dx.doi.org/10.1111/1759-7714.13943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169289/
https://www.ncbi.nlm.nih.gov/pubmed/33939301
http://dx.doi.org/10.1111/1759-7714.13943

Ejemplares similares